​

Novartis (NVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NVS Stock Forecast

Novartis (NVS) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $120.00, with a high of $120.00 and a low of $120.00. This represents a 9.51% increase from the last price of $109.58.

$95 $101 $107 $113 $119 $125 High: $120 Avg: $120 Low: $120 Last Closed Price: $109.58

NVS Stock Rating

Novartis stock's rating consensus is Hold, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (18.18%), 17 Hold (77.27%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Hold
Total 22 1 17 4 0 Strong Sell Sell Hold Buy Strong Buy

NVS Price Target Upside V Benchmarks

TypeNameUpside
StockNovartis9.51%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$116.75
Last Closing Price$109.58$109.58$109.58
Upside/Downside--6.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 251-92-12
Mar, 251-102-13
Feb, 25-1101-12
Jan, 25-1111-13
Dec, 24-1111-13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Etzer DaroutBMO Capital$120.00$109.919.18%9.51%
Sep 05, 2024James QuigleyGoldman Sachs$121.00$119.381.36%10.42%
Jul 19, 2024Etzer DaroutBMO Capital$118.00$106.1311.18%7.68%
Apr 23, 2024Wan NurhayatiCFRA$108.00$97.2711.03%-1.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025Deutsche BankHoldBuyupgrade
Feb 03, 2025BarclaysUnderweightUnderweighthold
Oct 30, 2024BMO CapitalMarket PerformMarket Performhold
Sep 05, 2024Goldman SachsBuyNeutraldowngrade
Sep 02, 2024JefferiesBuyHolddowngrade
Jul 19, 2024BMO CapitalMarket PerformMarket Performhold
Jul 19, 2024Deutsche BankHolddowngrade
Jul 12, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Jul 11, 2024Oddo BHFOutperformupgrade
Jul 02, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$3 $4 $5 $6 $7 $8 $9 $10 $11 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.55$10.71$3.19------
Avg Forecast$5.49$5.96$5.70$6.67$7.54$8.13$8.51$9.01$9.67
High Forecast$5.67$6.15$5.89$6.82$7.62$8.46$8.81$9.33$10.02
Low Forecast$5.32$5.77$5.55$6.55$7.50$8.04$8.29$8.78$9.43
Surprise %-35.34%79.70%-44.04%------

Revenue Forecast

$40B $44B $48B $52B $56B $60B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$49.90B$52.88B$51.83B$46.66B-----
Avg Forecast$49.25B$52.09B$51.52B$46.80B$50.44B$52.03B$53.14B$54.63B$55.82B
High Forecast$50.47B$53.38B$52.85B$53.04B$51.18B$52.60B$54.61B$56.14B$57.36B
Low Forecast$48.05B$50.82B$50.45B$43.97B$50.04B$51.47B$52.10B$53.56B$54.72B
Surprise %1.32%1.51%0.60%-0.30%-----

Net Income Forecast

$5B $11B $17B $23B $29B $35B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.07B$24.02B$6.96B$14.85B-----
Avg Forecast$7.64B$24.24B$25.22B$27.74B$15.77B$17.02B$17.79B$18.85B$20.24B
High Forecast$9.16B$29.08B$30.26B$33.29B$15.94B$17.69B$18.43B$19.52B$20.97B
Low Forecast$6.11B$19.39B$20.18B$22.19B$15.69B$16.81B$17.34B$18.37B$19.72B
Surprise %5.71%-0.89%-72.42%-46.47%-----

NVS Forecast FAQ

Is Novartis stock a buy?

Novartis stock has a consensus rating of Hold, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 17 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Novartis is a neutral investment for most analysts.

What is Novartis's price target?

Novartis's price target, set by 22 Wall Street analysts, averages $120 over the next 12 months. The price target range spans from $120 at the low end to $120 at the high end, suggesting a potential 9.51% change from the previous closing price of $109.58.

How does Novartis stock forecast compare to its benchmarks?

Novartis's stock forecast shows a 9.51% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for Novartis over the past three months?

  • April 2025: 8.33% Strong Buy, 0% Buy, 75.00% Hold, 16.67% Sell, 0% Strong Sell.
  • March 2025: 7.69% Strong Buy, 0% Buy, 76.92% Hold, 15.38% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 8.33% Buy, 83.33% Hold, 8.33% Sell, 0% Strong Sell.

What is Novartis’s EPS forecast?

Novartis's average annual EPS forecast for its fiscal year ending in December 2024 is $7.54, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $8.13 in 2025, $8.51 in 2026, $9.01 in 2027, and $9.67 in 2028.

What is Novartis’s revenue forecast?

Novartis's average annual revenue forecast for its fiscal year ending in December 2024 is $50.44B, reflecting a 8.09% increase from the reported $46.66B in 2023. The forecast for 2025 is $52.03B, followed by $53.14B for 2026, $54.63B for 2027, and $55.82B for 2028.

What is Novartis’s net income forecast?

Novartis's net income forecast for the fiscal year ending in December 2024 stands at $15.77B, representing an 6.20% increase from the reported $14.85B in 2023. Projections indicate $17.02B in 2025, $17.79B in 2026, $18.85B in 2027, and $20.24B in 2028.